Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2026
FDA approves Alvotech manufacturing process for SIMLANDI
The U.S. FDA approved Alvotech's Process 2.0 for manufacturing SIMLANDI (adalimumab-ryvk) drug substance at its Reykjavik facility. The process more than doubles output per batch without changing the upstream manufacturing scale.
2021
AbbVie files second suit against Alvotech
AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.
2021
Alvotech files suit against AbbVie over Humira patents
Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.
2021
Cipla Gulf expands biosimilar partnership with Alvotech
Cipla announced that its subsidiary Cipla Gulf was expanding its partnership with Alvotech to commercialize and distribute four biosimilar medicines in Australia and New Zealand. Alvotech develops and manufactures the products, and Cipla Gulf handles commercialization and distribution.
2020
JAMP Pharma and Alvotech sign Canadian biosimilar commercialization agreement
JAMP Pharma Group signed an exclusive agreement with Alvotech for the Canadian commercial rights to five biosimilars.